Munira Jahan

Munira Jahan

Auto-generated profile, based on publicly available information

Munira Jahan

Department of Virology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Research Focus & Metrics

Academic Career Length

57Years (1970-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SMSaif Ullah Munshi
Saif Ullah Munshi
TTThanh Thi Thanh Tran
Thanh Thi Thanh Tran
TVTruc Nhu Thanh Vo
Truc Nhu Thanh Vo
STShahina Tabassum
Shahina Tabassum
NSNahida Sultana
Nahida Sultana
MRMotiur Rahman
Motiur Rahman
The natural history and treatment outcome of hepatitis B viruses (HBV) infection is largely dependent on genotype, subgenotype, and the presence or absence of virulence associated mutations. We have studied the prevalence of genotype and subgenotype as well as virulence and drug resistance associated mutations and prevalence of recombinant among HBV from Bangladesh. A prospective cross-sectional study was conducted among treatment naïve chronic HBV patients attending at Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh for HBV viral load assessment between June and August 2015. Systematical selected 50% of HBV DNA positive patients (every second patient) were enrolled. Biochemical and serological markers for HBV infection and whole genome sequencing (WGS) was performed on virus positive sample. Genotype, subgenotype, virulence, nucleos(t)ide analogue (NA) resistance (NAr) mutations, and the prevalence of recombinant isolates were determined. Among 114 HBV DNA positive patients, 57 were enrolled in the study and 53 HBV WGS were generated for downstream analysis. Overall, 38% (22/57) and 62% (35/57) of patients had acute and chronic HBV infections, respectively. The prevalence of genotypes A, C, and D was 18.9% (10/53), 45.3% (24/53), and 35.8% (19/53), respectively. Among genotype A, C and D isolates subgenotype A1 (90%; 9/10), C1 (87.5%; 21/24) and D2 (78.9%; 15/19) predominates. The acute infection, virulence associated mutations, and viral load was higher in the genotype D isolates. Evidence of recombination was identified in 22.6% (12/53) of the HBV isolates including 20.0% (2/10), and 16.7% (4/24) and 31.6% (6/19) of genotype A, C and D isolates, respectively. The prevalence of recombination was higher in chronic HVB patients (32.2%; 10/31 versus 9.1%; 2/22); p<0.05. NAr mutations were identified in 47.2% (25/53) of the isolates including 33.9% novel mutations (18/53). HBV genotype C and D predominated in this population in Bangladesh; a comparatively high prevalence of recombinant HBV are circulating in this setting.

1 January 2011 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
SKSabera Khatun
Sabera Khatun
SHSyed Md Akram Hussain
Syed Md Akram Hussain
SCSameena Chowdhury
Sameena Chowdhury
JFJannatul Ferdous
Jannatul Ferdous
FHFawzia Hossain
Fawzia Hossain
AKA B M Fazlul Karim
A B M Fazlul Karim
Bangladesh has the highest level of incidence and mortality rates due to cervical cancer among women. The prevalence of cervical cancer in Bangladeshi women is 25–30/100 000. Human papillomavirus is an important cause of cervical cancer. The study was conducted to assess the immunogenicity and safety profile of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccines in healthy Bangladeshi girls aged 9–13 years. This was a randomized (3:1) controlled trial with two parallel groups, the vaccine and control groups, that included 67 participants in Bangladesh. Subjects were given GlaxoSmithKline human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine (and controls no vaccine) at the first day of vaccination (Day 0), at 1- and 6-month schedule and followed up until 7 months. Blood samples were taken for human papillomavirus antibody at enrollment and 1 month post-schedule at Month 7 from both subjects and controls. Safety data were gathered throughout the study period. Fifty subjects received vaccine at Day 0, 1 month and 6 months. All subjects were initially sero-negative in the vaccine group, and developed sero-conversion for human papillomavirus-16 and -18 antibodies except for one at Month 7. Seventeen controls did not receive vaccine. Clients were followed up for serious medically important events and blood samples were taken for human papillomavirus antibody detection at Day 0 and Month 7. Sero-conversion was found in 97.5% of subjects and no sero-conversion was found in the controls. Bivalent human papillomavirus vaccine was generally well tolerated, with no vaccine-related serious adverse experiences. The human papillomavirus-16/18 AS04-adjuvanted vaccine was generally well tolerated and highly immunogenic when administered to young adolescent females and could be a promising tool for the prevention and control of cervical cancer in Bangladesh.

23 October 2014 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
ANAshrafun Nessa
Ashrafun Nessa
MRMohammad Harun Ur Rashid
Mohammad Harun Ur Rashid
MJMunira Jahan
Munira Jahan
NFNoor-E Ferdous
Noor-E Ferdous
PNPervin Akhter Shamsun Nahar
Pervin Akhter Shamsun Nahar
ACAfroza Chowdhury
Afroza Chowdhury
Role of the HPV DNA Test in Follow-up of Treated Cervical Intraepithelial Neoplasia in Bangladesh HPV DNA test;follow-up;treated CIN;Bangladesh; Background: Cervical cancer is a major public health problem in Bangladesh. Persistence of high risk human papillomavirus (HRHPV) influences the progression of the disease, with an important role in followup for cervical intraepithelial neoplasia (CIN). Objective: To establish application of high risk HPV DNA test in the follow-up of women after treatment of CIN. Materials and Methods: This cross-sectional and hospital based study was carried out among 145 CIN treated women during the previous six months to three years at the colposcopy clinic of Bangabandhu Sheikh Mujib Medical University, Dhaka, between January 2011 and June 2012. Pap smear and HPV samples were collected and colposcopy was performed to find out the persistence of the disease. Cervical samples obtained were tested for HPV DNA using the Hybrid Capture II (HC-II) test. A cervical biopsy was collected whenever necessary. The results were compared to assess the efficacy of different methods during follow up such as Pap smear, HPV test and colposcopy. Results: Mean age of the recruited women (n=145) was 33.6 (${\pm}7.6$), mean age of marriage was 16.8 (${\pm}2.9$) and mean age of 1st delivery was 18.8 (${\pm}3.5$) years. More than half had high grade CIN before treatment and 115 (79.3%) women were managed by LEEP and 20.7% were managed by cold coagulation. Among the 145 treated women, 139 were negative for HPV DNA and six of them (4.1%) were HPV positive. Sensitivity of Pap smear (40.0) and HPV DNA test (40.0) was poor, but specificity was quite satisfactory (>93.0) for all the tests. Conclusions: The high risk HPV DNA test can be an effective method of identifying residual disease. It can be added to colposcopy and this should be applied to all treated women attending for their first or second post-treatment follow-up visit at 6 months to one year, irrespective of the grade of treated CIN.

1 August 2018 in Virus Research
Verified
Journal Article
Closed access
MSModhusudon Shaha
Modhusudon Shaha
HRHadisur Rahman
Hadisur Rahman
MJMunira Jahan
Munira Jahan
SDShuvra Kanti Dey
Shuvra Kanti Dey
KDKeshob Chandra Das
Keshob Chandra Das
MSMd Salimullah
Md Salimullah

1 June 2016 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
MJMunira Jahan
Munira Jahan
AIAsadul Islam
Asadul Islam
SASheikh Mohammad Fazle Akbar
Sheikh Mohammad Fazle Akbar
KTKazuaki Takahashi
Kazuaki Takahashi
STShahina Tabassum
Shahina Tabassum
MMMamun Al Mahtab
Mamun Al Mahtab

1 March 2018 in Microbiology Resource Announcements
Verified
Journal Article
Open access
MSModhusudon Shaha
Modhusudon Shaha
KDKeshob Chandra Das
Keshob Chandra Das
MHMd Saddam Hossain
Md Saddam Hossain
MJMunira Jahan
Munira Jahan
Abu HashemAbu Hashem
Abu Hashem
MSMd Salimullah
Md Salimullah
Hepatitis B virus (HBV) causes significant global health problems despite the presence of a potential vaccine. HBV chronic cases are increasing rapidly in developing countries like Bangladesh. Here, we report the complete genome sequence of an HBV genotype C strain isolated from a chronic patient identified at an outdoor hospital section.